Danoprevir ITMN-191 Selleck HCV Protease inhibitor CAS: 850876-88-9

CAS NO: 850876-88-9
Danoprevir ITMN-191 Selleck HCV Protease inhibitor
Chemical Name: RG7227, ITMN-191, RO5190591
Molecular Formula: C35H46FN5O9S
Formula Weight: 731.83
CAS No.: 850876-88-9
Description Review
Description

Danoprevir, also known as ITMN-191 or Selleck HCV Protease inhibitor (CAS: 850876-88-9), is an antiviral medication that is used to treat hepatitis C virus (HCV) infections. This product works by inhibiting the HCV protease enzyme, which is necessary for the virus to replicate.

Chemical name: N-[(1R)-3-methyl-2-(2-oxo-1,3-dioxolan-4-yl)butyl]-6-(pyridin-3-ylmethyl)-5,8-dioxo-5,8-dihydro-[1,2,4]triazolo[1,5-a]pyrimidine-2-carboxamide

Molecular formula: C29H30N8O6

Formula weight: 582.61 g/mol

CAS No: 850876-88-9

Top ten keywords from Google and Synonyms:

  1. Hepatitis C treatment
  2. Antiviral medication
  3. HCV protease inhibitor
  4. Danoprevir powder
  5. Selleck HCV Protease inhibitor
  6. ITMN-191
  7. Liver disease
  8. Direct-acting antiviral (DAA)
  9. Interferon-free therapy
  10. RNA polymerase inhibitors

Synonyms: ITMN-191, Selleck HCV Protease inhibitor, N-[(1R)-3-methyl-2-(2-oxo-1,3-dioxolan-4-yl)butyl]-6-(pyridin-3-ylmethyl)-5,8-dioxo-5,8-dihydro-[1,2,4]triazolo[1,5-a]pyrimidine-2-carboxamide

Health benefits of Danoprevir:

The primary health benefit of Danoprevir is its ability to inhibit the HCV protease enzyme, which is necessary for the virus to replicate. By doing so, this medication can help prevent the progression of liver disease and improve outcomes for patients with HCV.

Potential effects of Danoprevir:

Danoprevir works by inhibiting the HCV protease enzyme, which is necessary for the virus to replicate. In clinical trials, this medication has demonstrated significant antiviral activity, including rapid reductions in viral load and sustained virologic response rates. Additionally, Danoprevir may have the potential to be used in combination with other direct-acting antiviral medications for interferon-free therapy.

Product mechanism:

Danoprevir works by inhibiting the HCV protease enzyme, which is necessary for the virus to replicate. By doing so, this medication can help prevent the progression of liver disease and improve outcomes for patients with HCV. Additionally, Danoprevir may have the potential to be used in combination with other direct-acting antiviral medications for interferon-free therapy.

Safety:

Danoprevir is generally considered safe when taken as directed by a healthcare provider. However, like any medication, it does carry some risks and potential side effects. Before taking this medication, patients should discuss their medical history and any current medications with their healthcare provider to ensure that it is safe for them to take.

Side effects of Danoprevir:

Common side effects of Danoprevir include fatigue, headache, and gastrointestinal symptoms such as nausea and diarrhea. More serious side effects are rare, but may include allergic reactions, liver damage, and changes in blood cell counts. Patients who experience any of these symptoms while taking this medication should contact their healthcare provider immediately.

Dosing information:

The recommended dose of Danoprevir varies depending on the patient's medical history and condition. It is important for patients to follow their healthcare provider's instructions regarding dosing and administration of this medication.

Conclusion:

Danoprevir is an antiviral medication that is used to treat hepatitis C virus (HCV) infections. By inhibiting the HCV protease enzyme, this medication can help prevent the progression of liver disease and improve outcomes for patients with HCV. While generally considered safe, this medication does carry some risks and potential side effects, so patients should discuss their medical history and any current medications with their healthcare provider before taking it. Overall, Danoprevir is a promising medication that may hold significant potential for the treatment of HCV

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code
Message Us